Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Livmarli® (maralixibat) – Expanded indication
March 14, 2023 - Mirum Pharmaceuticals announced the FDA approval of Livmarli (maralixibat), for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older.
